Amgen Inc. (AMGN) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2024)
AMGN's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
By Geography
AMGN Revenue Analysis (2014–2025)
As of February 28, 2026, Amgen Inc. (AMGN) generated trailing twelve-month (TTM) revenue of $36.74 billion, reflecting solid growth of +8.6% year-over-year. The most recent quarter (Q4 2025) recorded $9.87 billion in revenue, up 3.2% sequentially.
Looking at the longer-term picture, AMGN's 5-year compound annual growth rate (CAGR) stands at +7.6%, indicating steady revenue expansion. The company achieved its highest annual revenue of $36.75 billion in 2025, representing a new all-time high.
Revenue diversification analysis shows AMGN's business is primarily driven by Other Products (17%), Prolia (13%), and ENBREL (10%).
When compared to Healthcare sector peers including ABBV (+7.4% YoY), GILD (+2.4% YoY), and NVO (+2.3% YoY), AMGN has outperformed the peer group in terms of revenue growth. Compare AMGN vs ABBV →
Peer Comparison
Compare AMGN's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| AMGNCurrent | $36.7B | +8.6% | +7.6% | 40.5% | |
| ABBV | $56.3B | +7.4% | +11.1% | 16.2% | |
| GILD | $28.8B | +2.4% | +5.1% | 5.8% | |
| NVO | $297.2B | +2.3% | +18.5% | 41.4% | |
| BIIB | $9.8B | +1.4% | -6.1% | 19.1% | |
| SCLX | $57M | -26.8% | - | -147.4% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $36.75B | +10.0% | $30.33B | 82.5% | $14.89B | 40.5% |
| 2024 | $33.42B | +18.6% | $20.57B | 61.5% | $7.26B | 21.7% |
| 2023 | $28.19B | +7.1% | $19.77B | 70.1% | $7.90B | 28.0% |
| 2022 | $26.32B | +1.3% | $19.92B | 75.7% | $9.57B | 36.3% |
| 2021 | $25.98B | +2.2% | $19.52B | 75.2% | $7.64B | 29.4% |
| 2020 | $25.42B | +8.8% | $19.27B | 75.8% | $9.14B | 35.9% |
| 2019 | $23.36B | -1.6% | $19.01B | 81.4% | $9.67B | 41.4% |
| 2018 | $23.75B | +3.9% | $19.65B | 82.7% | $10.26B | 43.2% |
| 2017 | $22.85B | -0.6% | $18.78B | 82.2% | $9.97B | 43.6% |
| 2016 | $22.99B | +6.1% | $18.83B | 81.9% | $9.79B | 42.6% |
See AMGN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs AMGN Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare AMGN vs AGIO
See how AMGN stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is AMGN's revenue growth accelerating or slowing?
AMGN maintains +8.6% revenue growth, in line with its 5-year CAGR of +7.6%. TTM revenue stands at $36.7B. Growth rate remains consistent with historical average.
What is AMGN's long-term revenue growth rate?
Amgen Inc.'s 5-year revenue CAGR of +7.6% reflects the sustained expansion pattern. Current YoY growth of +8.6% is near this long-term average.
How is AMGN's revenue distributed by segment?
AMGN reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.